Suppr超能文献

肝源性糖尿病:它是慢性肝病中一种被忽视的病症吗?

Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?

作者信息

García-Compeán Diego, González-González José Alberto, Lavalle-González Fernando Javier, González-Moreno Emmanuel Irineo, Villarreal-Pérez Jesús Zacarías, Maldonado-Garza Héctor Jesús

机构信息

Diego García-Compeán, José Alberto González-González, Emmanuel Irineo González-Moreno, Héctor Jesús Maldonado-Garza, Gastroenterology Service and Department of Internal Medicine, University Hospital "Dr. José E. González" and Medical School, Universidad Autónoma de Nuevo León, Monterrey 64320, México.

出版信息

World J Gastroenterol. 2016 Mar 14;22(10):2869-74. doi: 10.3748/wjg.v22.i10.2869.

Abstract

Diabetes mellitus (DM) that occurs because of chronic liver disease (CLD) is known as hepatogenous diabetes (HD). Although the association of diabetes and liver cirrhosis was described forty years ago, it was scarcely studied for long time. Patients suffering from this condition have low frequency of risk factors of type 2 DM. Its incidence is higher in CLD of viral, alcoholic and cryptogenic etiology. Its pathophysiology relates to liver damage, pancreatic dysfunction, interactions between hepatitis C virus (HCV) and glucose metabolism mechanisms and genetic susceptibility. It associates with increased rate of liver complications and hepatocellular carcinoma, and decreased 5-year survival rate. It reduces sustained virological response in HCV infected patients. In spite of these evidences, the American Diabetes Association does not recognize HD. In addition, the impact of glucose control on clinical outcomes of patients has not been evaluated. Treatment of diabetes may be difficult due to liver insufficiency and hepatotoxicity of antidiabetic drugs. Notwithstanding, no therapeutic guidelines have been implemented up to date. In this editorial, authors discuss the reasons why they think that HD may be a neglected pathological condition and call attention to the necessity for more clinical research on different fields of this disease.

摘要

由慢性肝病(CLD)引发的糖尿病(DM)被称为肝源性糖尿病(HD)。尽管糖尿病与肝硬化的关联在四十年前就已被描述,但长期以来对其研究甚少。患有这种疾病的患者2型糖尿病危险因素的发生率较低。在病毒、酒精和隐源性病因导致的CLD中,其发病率更高。其病理生理学与肝损伤、胰腺功能障碍、丙型肝炎病毒(HCV)与葡萄糖代谢机制之间的相互作用以及遗传易感性有关。它与肝脏并发症和肝细胞癌的发生率增加以及5年生存率降低相关。它会降低HCV感染患者的持续病毒学应答。尽管有这些证据,但美国糖尿病协会并不认可HD。此外,血糖控制对患者临床结局的影响尚未得到评估。由于肝功能不全和抗糖尿病药物的肝毒性,糖尿病的治疗可能会很困难。尽管如此,迄今为止尚未实施治疗指南。在这篇社论中,作者讨论了他们认为HD可能是一种被忽视的病理状况的原因,并呼吁关注对该疾病不同领域进行更多临床研究的必要性。

相似文献

1
Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?
World J Gastroenterol. 2016 Mar 14;22(10):2869-74. doi: 10.3748/wjg.v22.i10.2869.
5
Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?
Liver Int. 2017 Jul;37(7):950-962. doi: 10.1111/liv.13337. Epub 2016 Dec 31.
6
Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
World J Gastroenterol. 2015 Dec 14;21(46):12989-95. doi: 10.3748/wjg.v21.i46.12989.
7
[Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features].
Ter Arkh. 2019 Dec 15;91(12):115-121. doi: 10.26442/00403660.2019.12.000166.
8
Clinical implications of hepatogenous diabetes in liver cirrhosis.
J Gastroenterol Hepatol. 2002 Jun;17(6):677-81. doi: 10.1046/j.1440-1746.2002.02755.x.

引用本文的文献

1
Disorder of Glucose Metabolism and Therapy: Implications on the Natural History of Advanced Chronic Liver Disease.
GE Port J Gastroenterol. 2024 Oct 2;32(4):242-250. doi: 10.1159/000541211. eCollection 2025 Jul.
2
The mediating role of wellbeing in the relationship between health behaviors and quality of life in people with hepatogenous diabetes.
Front Public Health. 2025 May 30;13:1529158. doi: 10.3389/fpubh.2025.1529158. eCollection 2025.
3
[Hepatogenic diabetes: three cases report and literature review].
Probl Endokrinol (Mosk). 2025 May 20;71(2):66-74. doi: 10.14341/probl13443.
4
From cirrhosis to hepatogenous diabetes: risk factors and glycemic management.
Arch Med Sci. 2024 Jun 21;21(2):383-391. doi: 10.5114/aoms/189834. eCollection 2025.
5
Assessment of hepatic fibrosis with non-invasive indices in subjects with diabetes before and after liver transplantation.
Front Endocrinol (Lausanne). 2024 Mar 5;15:1359960. doi: 10.3389/fendo.2024.1359960. eCollection 2024.
6
Hepatogenous diabetes: Knowledge, evidence, and skepticism.
World J Hepatol. 2022 Jul 27;14(7):1291-1306. doi: 10.4254/wjh.v14.i7.1291.
7
Hepatogenous Diabetes - A Report from Central India.
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):312-318. doi: 10.1016/j.jceh.2021.08.018. Epub 2021 Aug 25.
9
Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus.
J Diabetes Res. 2021 Nov 11;2021:7692447. doi: 10.1155/2021/7692447. eCollection 2021.
10
Hepatogenous Diabetes: A Primer.
J Clin Exp Hepatol. 2021 Sep-Oct;11(5):603-615. doi: 10.1016/j.jceh.2021.04.012. Epub 2021 May 1.

本文引用的文献

1
Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis.
World J Gastroenterol. 2015 Nov 21;21(43):12361-9. doi: 10.3748/wjg.v21.i43.12361.
2
Alterations in carbohydrate metabolism in cirrhotic patients before and after liver transplant.
Diabetes Res Clin Pract. 2015 Nov;110(2):123-8. doi: 10.1016/j.diabres.2015.10.002. Epub 2015 Oct 9.
4
The treatment of diabetes mellitus of patients with chronic liver disease.
Ann Hepatol. 2015 Nov-Dec;14(6):780-8. doi: 10.5604/16652681.1171746.
5
Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease.
J Hepatol. 2015 Dec;63(6):1484-90. doi: 10.1016/j.jhep.2015.08.011. Epub 2015 Aug 20.
6
The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US.
Aliment Pharmacol Ther. 2014 Sep;40(6):686-94. doi: 10.1111/apt.12881. Epub 2014 Jul 16.
7
Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis.
World J Gastroenterol. 2014 Jun 14;20(22):7011-8. doi: 10.3748/wjg.v20.i22.7011.
10
Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):839-57. doi: 10.1517/17425255.2014.902444. Epub 2014 Mar 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验